Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-27T07:01:41.673Z Has data issue: false hasContentIssue false
  • English
  • Français

High Dose Tamoxifen in the Treatment of Recurrent High Grade Glioma: A Report of Clinical Stabilization and Tumour Regression

Published online by Cambridge University Press:  18 September 2015

Gordon Baltuch ,
George Shenouda ,
Adrian Langleben  and
Jean-Guy Villemure
Gordon Baltuch*
Affiliation:
Neurology and Neurosurgery (G.B., J.G.V.), Department of Radiation Oncology (G.S.), Department of Oncology (A.L.), McGill University, Montreal
George Shenouda
Affiliation:
Neurology and Neurosurgery (G.B., J.G.V.), Department of Radiation Oncology (G.S.), Department of Oncology (A.L.), McGill University, Montreal
Adrian Langleben
Affiliation:
Neurology and Neurosurgery (G.B., J.G.V.), Department of Radiation Oncology (G.S.), Department of Oncology (A.L.), McGill University, Montreal
Jean-Guy Villemure
Affiliation:
Neurology and Neurosurgery (G.B., J.G.V.), Department of Radiation Oncology (G.S.), Department of Oncology (A.L.), McGill University, Montreal
*
Montreal Neurological Institute, 3801 University St., Montreal, Quebec, Canada H3A 2B4
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We present a case of recurrent glioma, previously treated with maximal surgery and radiation in which a high dose of tamoxifen has stabilized the tumour clinically and has resulted in it's radiologic regression. Given tamoxifen's relative lack of toxicity, it might serve as a useful adjuvant in the treatment of recurrent glioma.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 20 , Issue 2 , May 1993 , pp. 168 - 170
Copyright
Copyright © Canadian Neurological Sciences Federation 1993

References

1.Barba, D, Saris, SC, Holder, C, Rosenberg, SA, Oldfield, EH. Intratumoural LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989; 70: 175–182.CrossRefGoogle ScholarPubMed
2.Mahaley, MS, Hipp, SW, Dropcho, EJ, et al.Intracarotid cisplatinum chemotherapy for recurrent gliomas. J Neurosurg 1989; 70: 371–378.CrossRefGoogle ScholarPubMed
3.Gutin, PH, Leibel, SA, Wara, WM, et al.Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg 1987; 67: 864–873.CrossRefGoogle ScholarPubMed
4.Brem, H, Mahaley, MS, Vick, NA, et al.Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991; 74: 441–446.CrossRefGoogle ScholarPubMed
5.Legha, SS, Tamoxifen in the treatment of breast cancer. Ann Intern Med 1988; 109: 219–228.CrossRefGoogle ScholarPubMed
6.Rowlands, MG, Parr, IB, McGague, R, et al.Variation of inhibition of calmodulin-dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlates with cytotoxicity. Biochem Pharmacol 1990; 49: 283–289.CrossRefGoogle Scholar
7.Sutherland, RL, Murphy, LC, Foo, MS, et al.High affinity antiestrogen binding site distinct from the estrogen receptor. Nature 1980; 288: 273–275.CrossRefGoogle Scholar
8.Butta, A, MacLennan, K, Flanders, KC, et al.Induction of transforming growth factor (31 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261–4264.Google Scholar
9.O'Brian, CA, Liskamp, RM, Soloman, DH, Weinstein, IB, Inhibition of protein kinase C by tamoxifen. Cancer Res 1985; 45: 2462–2465.Google ScholarPubMed
10.Su, HD, Mazzei, GJ, Vogler, WR, et al.Effects of tamoxifen, a non-steroidal anti-estrogen on phospholipid/calcium-dependent protein kinase and phophorylation of its endogenous substrate proteins from rat brain and ovary. Biochem Pharmacol 1985; 34: 3649–3653.Google Scholar
11.Horgan, K, Cooke, E, Hallett, MB, Mansel, RE. Inhibition of protein-kinase C mediated signal transduction by tamoxifen. Biochem Pharmacol 1986; 35: 4463–4465.CrossRefGoogle ScholarPubMed
12.Weinstein, IB. The role of protein kinase C in growth control and the concept of carcinogenesis as a progressive disorder in signal transduction. Advances in second messenger and phosphoprotein research. 1990; 24: 307–316.Google ScholarPubMed
13.Couldwell, WT, Uhm, JH, Antel, JP, Yong, VW. Enhanced protein kinase C activity correlates with the growth of malignant glioma in vino. Neurosurgery 1991; 29: 880–887.CrossRefGoogle Scholar
14.Couldwell, WT, Antel, JP, Yong, VW. Enhanced protein kinase C activity correlates with the growth rate of malignant human gliomas. Effects of glioma mitogens and modulators of PKC. Neurosurgery 1992; 31: 717–724.Google Scholar
15.Pollack, IF, Randall, MS, Kristofik, MP, et al.Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 1990; 50: 7134–7138.Google ScholarPubMed
16.Baituch, GH, Couldwell WT, Villemure, J-G, Yong, VW. Protein kinase C inhibitors suppress cell growth in established and low passage glioma cell lines: a comparison between staurosporine and tamoxifen. Neurosurgery 1993 (in press).CrossRefGoogle Scholar
17.Berd, D, McLaughlin, CJ, Hart, E, et al.Short course high dose tamoxifen with cytotoxic chemotherapy for metastatic melanoma. Proc ASCO 1991; 10: 291.Google Scholar
18.Knabbe, C, Lippman, ME, Wakefield, LM, et al.Evidence that TGF-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417–428.CrossRefGoogle ScholarPubMed
19.Vertosick, FT, Selker, RG, Pollack, IF, Arena, V. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of “failed” patients. Neurosurgery 1992; 30: 897–903.Google Scholar
20.Corey, RW, Davis, JM, Zervas, NT. Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Treatment Rep 1981; 65: 793–795.Google Scholar
21.Hansen, SB, Gulsgard, H, Van, Eyben FE, et al.Tamoxifen for brain metastases from breast cancer. Ann Neurol 1986; 20: 544.CrossRefGoogle ScholarPubMed
22.Trump, DL, Smith, DC, Schold, SC, et al.High dose tamoxifen and five day continuous infusion of vinblastine: a phase/trial of an inhibitor of the MDR-1 phenotype. Proc ASCO 1991; 10: 96.Google Scholar